Spots Global Cancer Trial Database for lymphocytic
Every month we try and update this database with for lymphocytic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | NCT01149668 | Lymphoma Non-Hodgkin's L... Hodgkin Disease Multiple Myelom... Leukemia Lymphocytic | PCI-24781 | 18 Years - | Pharmacyclics LLC. | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | NCT00768339 | Leukemia, Lymph... Lymphoma, B-Cel... | AEG35156 antise... | 18 Years - | Aegera Therapeutics | |
| Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells | NCT00224354 | CHRONIC LYMPHOC... | IL-2 secreting ... IL-2 CD40L ONTAK immunotoxin dos... | 18 Years - | Baylor College of Medicine | |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | NCT00021749 | Chronic Lymphoc... CLL | Oblimerson sodi... | 18 Years - | Genta Incorporated | |
| Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | NCT00078234 | Chronic Lymphoc... | Oblimersen-ritu... | 18 Years - | Genta Incorporated | |
| Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL | NCT00881920 | Lymphoma Myeloma Leukemia | Kappa CD28 T ce... | 18 Years - | Baylor College of Medicine | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia | NCT01600053 | Chronic Lymphoc... | Lenalidomide | 18 Years - | University of California, San Diego | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | NCT03514017 | Chronic Lymphoc... | Pembrolizumab Ibrutinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | NCT00021749 | Chronic Lymphoc... CLL | Oblimerson sodi... | 18 Years - | Genta Incorporated | |
| Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | NCT03759184 | Leukemia Lymphocytic Chronic B-Cell | rhIL-15 rhIL-15 Obinutuzumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | NCT00768339 | Leukemia, Lymph... Lymphoma, B-Cel... | AEG35156 antise... | 18 Years - | Aegera Therapeutics | |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | NCT00768339 | Leukemia, Lymph... Lymphoma, B-Cel... | AEG35156 antise... | 18 Years - | Aegera Therapeutics | |
| Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | NCT03759184 | Leukemia Lymphocytic Chronic B-Cell | rhIL-15 rhIL-15 Obinutuzumab | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
